(+)-JQ-1 is a highly potent and selective BET bromodomain BRD2/4 inhibitor that showed activity impairing mouse macrophage inflammatory response [1], activating HIV latency [2], and blocking the BET mediated acetylation and transcriptions of c-Myc [3].
Technical information:
| Chemical Formula: |
C23H25ClN4O2S |
|
| CAS #: | 1268524-70-4 | |
| Molecular Weight: | 456.99 | |
| Purity: | > 98% | |
| Appearance: | White | |
| Chemical Name: | (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester | |
| Solubility: | Up to 100 mM in DMSO | |
| Synonyms: | JQ1 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
Reference:
| 1. | Anna C, et al. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol. 2013; 190(7): 3670–3678. Pubmed ID: 23420887 |
| 2. | Li Z, et al, The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013; 41(1): 277–287. Pubmed ID: 23087374 |
| 3. | Alqahtani A, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019; 5(3): FSO372 Pubmed ID: 30906568 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
